Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Case Rep Gastroenterol ; 12(2): 234-239, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29928189

RESUMEN

Esophageal large-cell neuroendocrine carcinoma (NEC) is a rare malignant tumor that is characterized by high-grade malignancy and a poor prognosis. However, the rarity of esophageal NEC has prevented the development of an established treatment, and no reports have described a discrepancy in the effectiveness of cisplatin plus irinotecan between primary and metastatic lesions. A 43-year-old Japanese man was referred to our hospital with refractory epigastralgia. A previous gastrointestinal endoscopy had revealed a 50-mm type 2 tumor in the abdominal esophagus. The pathological findings indicated poorly differentiated squamous cell carcinoma. Contrast-enhanced computed tomography revealed a metastatic liver tumor. One cycle of fluorouracil and cisplatin was not effective, and endoscopy was repeatedly performed. The pathological findings indicated a large-cell malignant tumor with tumor cells that were positive for CD56, synaptophysin, and Ki-67 (> 80%). Based on a diagnosis of esophageal large-cell NEC with a metastatic liver tumor, the patient received cisplatin plus irinotecan biweekly. After 4 months, computed tomography revealed marked shrinkage of the metastatic tumor, but the patient complained of dysphagia. Endoscopy revealed enlargement of the primary tumor, which was then treated using radiotherapy plus fluorouracil and cisplatin. The primary tumor subsequently shrank, and the patient's symptoms were relieved, but the metastatic tumor grew. Thus, chemoradiotherapy could be an option for managing a primary esophageal large-cell NEC that does not respond to chemotherapy alone. However, the possibility of an inconsistent response to therapy in primary and metastatic lesions should be considered.

2.
Intern Med ; 56(22): 3023-3026, 2017 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-29021429

RESUMEN

The patient was a 76-year-old woman who had noticed slight difficulty in swallowing in the 3 years prior to this presentation. Her dysphagia progressed while she was hospitalized following cervical cancer surgery. Esophagogastroduodenoscopy and an esophagram showed circumferential erosion and a stricture of the thoracic esophagus. Esophageal resection was performed; the resected specimens showed a stricture and wall thickening. Histologically, transmural hyperplasia, which consisted of inflammatory granulation tissue with the abundant infiltration of IgG4-positive plasma cells and lymphocytes, was observed. The patient was diagnosed with probable IgG4-related disease. IgG4-related esophageal disease presenting as esophageal lesions alone is a very rare condition.


Asunto(s)
Enfermedades Autoinmunes/patología , Esofagitis/patología , Inmunoglobulina G/sangre , Células Plasmáticas/inmunología , Anciano , Enfermedades Autoinmunes/sangre , Esofagitis/sangre , Femenino , Humanos , Células Plasmáticas/patología
3.
Intern Med ; 54(21): 2711-5, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26521898

RESUMEN

A 74-year-old man was diagnosed with small cell carcinoma arising from the extrahepatic bile duct according to a histological examination of the biopsy specimen obtained during endoscopic retrograde cholangiopancreatography. Additionally, bulky hilar lymphadenopathy was observed, and the patient was treated with the combination of radiation and chemotherapy (cisplatin and irinotecan). Post-therapy, he underwent pancreaticoduodenectomy. The histological examination of the resected specimen revealed no residual cancer cells in the bile duct wall and a small amount of cancer cells in only a single lymph node. Due to this multidisciplinary therapy, the patient showed no signs of recurrence 12 months postoperatively.


Asunto(s)
Neoplasias de los Conductos Biliares/diagnóstico , Neoplasias de los Conductos Biliares/terapia , Conductos Biliares Extrahepáticos , Carcinoma de Células Pequeñas/diagnóstico , Carcinoma de Células Pequeñas/terapia , Conducto Colédoco/patología , Pancreaticoduodenectomía , Anciano , Antineoplásicos/administración & dosificación , Neoplasias de los Conductos Biliares/tratamiento farmacológico , Neoplasias de los Conductos Biliares/radioterapia , Conductos Biliares Extrahepáticos/diagnóstico por imagen , Camptotecina/administración & dosificación , Camptotecina/análogos & derivados , Carcinoma de Células Pequeñas/tratamiento farmacológico , Carcinoma de Células Pequeñas/radioterapia , Colangiopancreatografia Retrógrada Endoscópica , Cisplatino/administración & dosificación , Humanos , Irinotecán , Masculino , Recurrencia Local de Neoplasia/prevención & control , Pancreaticoduodenectomía/métodos , Fármacos Sensibilizantes a Radiaciones/administración & dosificación , Resultado del Tratamiento
13.
Med Mol Morphol ; 38(4): 262-6, 2005 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-16378236

RESUMEN

A case of a patient with papillary renal cell carcinoma (RCC) with eosinophilic inclusions is presented. Almost all neoplastic cells contained eosinophilic globules that were stained red by trichrome and were negative for periodic acid-Schiff (PAS) reaction. Immunohistochemically, globules were negative for actin, keratin, vimentin, glially fibrillary acidic protein (GFAP), and neurofilament. Ultrastructurally, globules consisted of electron-dense granular material that is more suggestive of a secretory substance than cytoskeletal filaments. The presence of eosinophilic cytoplasmic inclusions in RCC is rare. In this article, we review similar cases in the literature and discuss the nature of eosinophilic globules.


Asunto(s)
Carcinoma de Células Renales/patología , Eosinófilos/patología , Cuerpos de Inclusión/patología , Neoplasias Renales/patología , Anciano de 80 o más Años , Carcinoma de Células Renales/ultraestructura , Eosinófilos/ultraestructura , Humanos , Cuerpos de Inclusión/ultraestructura , Japón , Neoplasias Renales/ultraestructura , Masculino
14.
Anticancer Res ; 25(3B): 2269-76, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16158974

RESUMEN

BACKGROUND: The mammalian lignan enterolactone (ENL) is produced from plant lignans which are present in large amounts in flaxseed (linseed). The effect of ENL on colon cancer cell growth in vitro and in vivo, and its mechanisms of action, have not been studied in detail. MATERIALS AND METHODS: The growth of the colo 201 human colon cancer cell line was examined by colorimetric 3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2- (4-sulphophenyl)-2H-tetrazolium (MTS) assay, while the expression of apoptosis- and proliferation-related proteins (p53, Bax, Bcl-xL and S, Bcl-2, Caspase-8, Caspase-3 and proliferating cell nuclear antigen (PCNA)) were examined by Western blotting. In vivo tumor growth was examined by transplanting colo 201 cells into ENL-treated and placebo-treated athymic mice. RESULTS: The MTS assay showed that ENL suppressed colo 201 cell growth (IC50 for 72 h: 118.4 microM) in vitro. On flow cytometry, induction of apoptosis was confirmed by the appearance of subG1 populations, while cell cycle progression was not affected. The expression of an apoptosis-suppressing protein (Bcl-2) was down-regulated, an apoptosis-enhancing protein (cleaved form of Caspase-3) was up-regulated, proliferation-related PCNA protein was down-regulated and p53, Bax, Bcl-xL and S and Caspase-8 levels were unchanged. ENL, at a dose of 10 mg/kg given 3 times per week by subcutaneous injection, significantly inhibited the growth of colo 201 cells transplanted into athymic mice without any adverse effects. CONCLUSION: ENL suppressed colo 201 human colon cancer cell growth both in vitro and in vivo. The tumor-suppressing mechanisms included apoptosis and decreased cell proliferation.


Asunto(s)
4-Butirolactona/análogos & derivados , Adenocarcinoma/tratamiento farmacológico , Apoptosis/efectos de los fármacos , Neoplasias del Colon/tratamiento farmacológico , Lignanos/farmacología , 4-Butirolactona/farmacología , Adenocarcinoma/patología , Animales , Caspasa 3 , Caspasa 8 , Caspasas/metabolismo , Procesos de Crecimiento Celular/efectos de los fármacos , Línea Celular Tumoral , Neoplasias del Colon/patología , Ciclina D1/metabolismo , Citometría de Flujo , Humanos , Ratones , Ratones Desnudos , Antígeno Nuclear de Célula en Proliferación/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Proteína X Asociada a bcl-2 , Proteína bcl-X
15.
Med Mol Morphol ; 38(2): 130-3, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15944821

RESUMEN

Although keratinous cysts of the skin are frequently seen, malignant transformation is a rare event. Here we report a case of basal cell carcinoma arising in the wall of the keratinous cyst, and we review 12 other such Japanese cases.


Asunto(s)
Carcinoma Basocelular/patología , Quiste Epidérmico/patología , Neoplasias Cutáneas/patología , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad
16.
In Vivo ; 19(3): 487-94, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15875766

RESUMEN

BACKGROUND: There have been no previous reports comparing the effects of prepubertal xenoestrogen exposure on development of the reproductive tract and mammary glands in female mice. The effects of genistein (GEN), resveratrol (RES), zearalenone (ZEA), zeranol (ZER), bisphenol A (BPA) and diethylstilbestrol (DES) were examined. MATERIALS AND METHODS: Beginning at 15 days of age, female CD-1 mice were administered 4 daily subcutaneous injections of 10 mg/kg/day of GEN, RES, ZEA, ZER or BPA, or 10 microg/kg/day of DES dissolved in dimethylsulfoxide (DMSO), or DMSO vehicle. Vaginal opening was checked; estrous cyclicity was monitored from 5, 9 or 21 weeks of age for 21 consecutive days; 6 animals per group were autopsied at 4, 8 and 24 weeks of age. RESULTS: Prepubertal exposure to GEN, ZEA, ZER and DES (but not RES or BPA) accelerated puberty onset (vaginal opening). Vaginal smears indicated that all xenoestrogen-treated mice were cycling, but ZEA-, ZER- and DES-treated mice spent more time in estrus. At 4 weeks of age, absence of corpora lutea (anovulatory ovary) was observed in the untreated controls (33%, 2/6) and the GEN (50%, 3/6), RES (50%, 3/6), ZEA (100%, 6/6), ZER (100%, 6/6), BPA (83%, 5/6) and DES groups (100%, 6/6). At 8 weeks of age, absence of corpora lutea was observed in the ZEA (33%, 2/6) group. Corpora lutea were present in all mice sacrificed at 24 weeks of age. Groups that received prepubertal xenoestrogen injections exhibited no morphological abnormalities of the uterus and vagina, and exhibited mammary gland growth similar to that of the untreated controls at all time-points. CONCLUSION: GEN, ZEA, ZER and DES (but not RES or BPA) caused early vaginal opening; mice exposed to ZEA, ZER or DES spent more time in the estrus phase; ZEA-treated mice had a longer period of anovulatory ovary than other xenoestrogen-treated mice; however, none of the xenoestrogens tested altered the uterine or vaginal morphology or mammary gland growth.


Asunto(s)
Dietilestilbestrol/farmacología , Estrógenos no Esteroides/farmacología , Estro/efectos de los fármacos , Genisteína/farmacología , Estilbenos/farmacología , Vagina/fisiología , Zearalenona/farmacología , Zeranol/farmacología , Animales , Compuestos de Bencidrilo , Femenino , Inyecciones Subcutáneas , Glándulas Mamarias Animales/efectos de los fármacos , Glándulas Mamarias Animales/crecimiento & desarrollo , Ratones , Fenoles/farmacología , Resveratrol , Maduración Sexual/efectos de los fármacos , Vagina/efectos de los fármacos
17.
Nutr Cancer ; 50(1): 71-9, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15572300

RESUMEN

The effect of conjugated docosahexaenoic acid (CDHA) on the inhibition of colon cancer cell growth was examined in the colo 201 human colon cancer cell line, and the effect was compared with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). CDHA was a more potent tumor cell growth inhibitor than DHA and EPA by colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (IC50 for 72 h: 31.6 microM, 46.8 microM, and 56.6 microM, respectively). CDHA inhibited cell cycle progression, due to accumulation of cells in G1 phase, which involved increased p21Cip1/Waf1 and decreased cyclin D1, cyclin E, and proliferating cell nuclear antigen expression; the p53 and cyclin A levels were unchanged. Induction of apoptosis was confirmed by the appearance of sub-G1 populations, and apoptosis cascade involved upregulation of the apoptosis-enhancing proteins (Bak and Bcl-xS) and downregulation of the apoptosis-suppressing proteins (Bcl-xL and Bcl-2). CDHA modulated cell cycle regulatory proteins and apoptosis-related proteins, similar to the effects of DHA. CDHA at a dietary dose of 1.0% significantly inhibited growth of colo 201 cells transplanted in nude mice.


Asunto(s)
Apoptosis/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Ciclinas/metabolismo , Ácidos Docosahexaenoicos/farmacología , Ácido Eicosapentaenoico/farmacología , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Animales , Proteínas de Ciclo Celular/metabolismo , División Celular/efectos de los fármacos , Línea Celular Tumoral , Ácidos Docosahexaenoicos/química , Relación Dosis-Respuesta a Droga , Citometría de Flujo , Humanos , Isomerismo , Masculino , Ratones , Ratones Desnudos , Trasplante de Neoplasias
18.
Oncol Rep ; 12(5): 1079-85, 2004 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15492796

RESUMEN

The dietary effects of conjugated docosahexaenoic acid (CDHA) were examined in an N-methyl-N-nitrosourea (MNU)-induced rat mammary carcinogenesis model. Female Sprague-Dawley rats were administered 50 mg/kg MNU intraperitoneally at 49 days of age. A powdered AIN-76A diet containing 0, 0.2 or 1.0% CDHA was fed to the rats from 21 to 49 days of age (before MNU; pre-initiation phase) or from 49 days to 40 weeks of age (after MNU; post-initiation phase). Rats were sacrificed when their largest mammary tumor was > or =1 cm in size or when they reached 40 weeks of age. All histologically detected mammary carcinomas were evaluated. In rats that received CDHA after MNU, development of mammary carcinoma > or =1 cm was inhibited, and there was a significant decrease in the final mammary cancer incidence and multiplicity, compared with rats that did not receive CDHA. Consumption of the 0.2% CDHA diet after MNU significantly prolonged latency. Suppression of mammary cancer yield by consumption of a CDHA diet after MNU administration was not dose-dependent. In rats that received CDHA before MNU, suppression of mammary cancer was not observed. These results indicate that CDHA administration in the post-initiation period suppressed mammary carcinogenesis, whereas CDHA administration in the pre-initiation period was ineffective.


Asunto(s)
Alquilantes/toxicidad , Anticarcinógenos/administración & dosificación , Dieta , Ácidos Docosahexaenoicos/administración & dosificación , Neoplasias Mamarias Experimentales/prevención & control , Metilnitrosourea/toxicidad , Animales , Femenino , Neoplasias Mamarias Experimentales/patología , Ratas , Ratas Sprague-Dawley
19.
Reprod Toxicol ; 18(6): 803-11, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15279878

RESUMEN

The objective of this study was to examine the effects of maternal exposure to xenoestrogen, at levels comparable to or greater than human exposure, on development of the reproductive tract and mammary glands in female CD-1 mouse offspring. Effects of genistein (GEN), resveratrol (RES), zearalenone (ZEA), bisphenol A (BPA) and diethylstilbestrol (DES) were examined. Beginning on gestational day 15, pregnant CD-1 mice were administered four daily subcutaneous injections with 0.5 or 10 mg/kg/day of GEN, RES, ZEA or BPA, 0.5 or 10 microg/kg/day of DES dissolved in dimethylsulfoxide (DMSO), or DMSO vehicle (n = 6). Vaginal opening was monitored, 6 animals per group were autopsied at 4, 8, 12 and 16 weeks of age and estrous cyclicity was monitored from 9 to 11 weeks of age. Maternal exposure to xenoestrogen accelerated puberty onset (vaginal opening) and increased the length of the estrous cycle; mice treated with GEN, RES, BPA or DES spent more time in diestrus, and ZEA-treated mice spent more time in estrus. Lack of corpora lutea and vaginal cornification were observed at 4 weeks of age in the high-dose GEN (33%) and RES (17%) groups, and in the high- and low-dose BPA groups (33 and 50%, respectively) and DES groups (83 and 100%, respectively). Lack of corpora lutea and vaginal cornification was observed in the high-dose ZEA group at 4, 8, 12 and 16 weeks of age (83, 100, 83 and 33%, respectively). Mammary gland differentiation was accelerated in ZEA- and BPA-treated mice with corpora lutea at 4 weeks of age. ZEA-treated mice without corpora lutea showed mammary growth arrest at 8, 12 and 16 weeks of age; their mammary glands consisted only of a dilatated duct filled with secreted fluid. Mammary gland growth was similar with xenoestrogens other than ZEA or BPA to that of the controls at all time points. High-dose GEN and RES and high- and low-dose BPA and DES exerted transient effects on the reproductive tract and mammary glands, whereas ZEA exerted prolonged effects.


Asunto(s)
Estrógenos no Esteroides/toxicidad , Genitales Femeninos/crecimiento & desarrollo , Xenobióticos/toxicidad , Animales , Compuestos de Bencidrilo , Cuerpo Lúteo/efectos de los fármacos , Dietilestilbestrol/toxicidad , Receptor alfa de Estrógeno/efectos de los fármacos , Ciclo Estral/efectos de los fármacos , Femenino , Genisteína/toxicidad , Genitales Femeninos/efectos de los fármacos , Inyecciones Subcutáneas , Glándulas Mamarias Animales/efectos de los fármacos , Glándulas Mamarias Animales/crecimiento & desarrollo , Ratones , Ratones Endogámicos ICR , Fenoles/toxicidad , Embarazo , Resveratrol , Estilbenos/toxicidad , Vagina/anatomía & histología , Vagina/efectos de los fármacos , Aumento de Peso/efectos de los fármacos , Zearalenona/farmacología
20.
Pathol Int ; 54(8): 623-9, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15260854

RESUMEN

A case of malignant rhabdoid tumor (MRT) occurring as a primary hepatic neoplasm in a 12-month-old Japanese female infant is presented. The patient had a slight fever for 2 weeks and presented with a palpable mass in her left hypochondrial region. After admission, the hepatic artery was embolized due to intra-abdominal hemorrhage arising from the tumor. The patient received chemotherapy with cisplatin, cyclophosphamide and adriacin. Despite treatment, the patient developed dyspnea, pancytopenia and disseminated intravascular coagulation. Rupture of the tumor resulted in death within 3 weeks. A limited abdominal autopsy revealed that the liver weighed 1240 g and was occupied by multiple hemorrhagic and/or necrotic tumor nodules. Histologically, neoplastic cells had an abundant eosinophilic cytoplasm containing paranuclear inclusions, and vesicular nuclei with a centrally located prominent nucleolus. Ultrastructurally, the cytoplasmic inclusions were composed of whorled filaments measuring 10 nm. Immunohistochemically, almost all of the neoplastic cells were positive for vimentin and cytokeratins (CK) 8 and 18, some were positive for CK 7 and 19, while none were positive for CK 1, 10, 13-17 and 20. The tumor cells did not express desmin, myoglobin, and alpha-fetoprotein. We found 18 cases of MRT of the liver published in English language literature and then, adding the present case, we summarized the 19 cases. Hepatic MRT is an uncommon neoplasm. However, it should be considered in the differential diagnosis of an aggressive liver neoplasm in childhood.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Hepáticas/patología , Tumor Rabdoide/patología , Biomarcadores de Tumor/análisis , Cisplatino/administración & dosificación , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Resultado Fatal , Femenino , Hemorragia/patología , Humanos , Inmunohistoquímica , Cuerpos de Inclusión/ultraestructura , Lactante , Neoplasias Hepáticas/química , Neoplasias Hepáticas/tratamiento farmacológico , Tumor Rabdoide/química , Tumor Rabdoide/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA